Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Krka is keen to expand its geographic presence beyond its stronghold in Europe, especially by capitalising on the “huge opportunity” in China. But it has no immediate plans to build a major presence in the Americas, according to the Slovenian group’s management board member David Bratoz.
Sun’s managing director, Dilip Shanghvi, has defended the “underlying health” of the company after a sizeable charge linked to antitrust litigation almost completely wiped out Sun’s pre-tax profit in its financial second quarter, while a sales decline in India limited overall turnover growth.
Nichi-Iko has started promoting the value-added portfolio of Eisai’s Elmed in Japan under a strategic alliance struck earlier this year that also includes Nichi-Iko acquiring all shares in Elmed by 1 April 2019. As part of the “phased acquisition” (Generics bulletin, 6 April 2018, page 3), Nichi-Iko said it had by 1 October acquired a third of stocks in Elmed for a total of ¥5.47 billion (US$48.7 million).
Significant sales increases for products launched in its previous financial year helped Towa to register turnover up by a tenth to ¥49.1 billion (US$435 million) in its financial first half ended 30 September 2018. Products launched in 2017 – including telmisartan, miglitol and orodispersible olmesartan – accounted for ¥3.6 billion of first-half sales, up from ¥1.2 billion in the first half in 2017. Meanwhile, more recent launches from 2018, such as lamotrigine and minodronic acid, generated sales of ¥0.8 billion.
Introducing its Enoxaparin Becat biosimilar in both Spain and France during September this year – in the latter market through partner Biogaran – enabled Laboratorios Farmacéuticos Rovi to report turnover from the low molecular weight heparin (LMWH) of €7.8 million (US$8.9 million) in the third quarter, and €16.7 million in the first nine months, of this year. The Spanish firm has also just rolled out Becat in Austria and Latvia.
Concordia International no longer faces a UK probe into “alleged anti-competitive agreements and/or concerted practices” for three of the firm’s products – trazodone, nefopam and dicycloverine – after the country’s Competition and Markets Authority (CMA) closed an investigation on “administrative priority grounds”.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.